Johnson & Johnson's former consumer unit, Kenvue Inc KVUE, reported its first quarterly earnings after being spun off in May.
Q2 sales increased 5.4% Y/Y to $4.01 billion, a Y/Y increase of 5.4%, beating the consensus of $3.96 billion. Foreign currency fluctuations negatively impacted net sales by approximately 2.3%. Organic growth increased by 7.7%.
Net sales at Kenvue's self-care business, which houses over-the-counter products or nonprescription medicines, jumped 12.2% due to increased demand from higher cough, cold, and flu cases.
Also Read: Kenvue's Growth Forecast: Exploring The Future Of Johnson & Johnson's Carve-Out.
The adjusted gross profit margin was 57.5% vs. 59.3% in 2022, dragged by a strong dollar and higher costs. Adjusted EBITDA margin was 24.5% vs. 26.8%.
Adjusted earnings per share was $0.32, beating the consensus of $0.30.
J&J, which owns about 90% of Kenvue's outstanding shares, said it intends to "split off" the shares through an exchange offer as the form of its next step in the separation, subject to market conditions.
Dividend: The company also declared a $0.20 cash dividend payable on September 7 with a record date of August 28.
Guidance: The company sees fiscal 2023 reported net sales growth of 4.5%-5.5%, with organic growth of 5.5% - 6.5%. It forecasts FY23 adjusted profit per share of $1.26 - $1.31 compared to the consensus of $1.23.
Price Action: KVUE shares are down 1.36% at $25.34 during the premarket session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.